Tactile Systems launches next-generation Nimbl platform

Tactile Systems Technology announced that Nimbl, its next-generation pneumatic compression platform, is now commercially available throughout the United States for the treatment of upper extremity lymphedema. Nimbl, which is significantly smaller and lighter than previous device iterations, is indicated as a treatment option for patients with both upper and lower extremity lymphedema, chronic edema, venous insufficiency, and wound healing. Nimbl received U.S Food & Drug Administration 510(k) clearance in June 2024 and Pricing, Data Analysis, and Coding approval from the Centers for Medicare & Medicaid Services in September 2024. The Company expects to make Nimbl commercially available for patients with lower extremity conditions in the coming months. Nimbl is 68% lighter, 40% smaller, and uses 33% less hosing than the Company’s current generation basic pneumatic compression device. Its compact design is the smallest PCD of its kind, making it an ideal therapy for daily use at home or on the go. In addition to the patient centric feature enhancements, Nimbl also offers connectivity to the Company’s free Kylee digital application, providing patients a simple way to track their usage and change in symptoms, and to share results with their care team. Convenient accessories are available for purchase including a rechargeable battery and custom-designed travel bag.